DICE vs. NUVL, JANX, VYGR, FATE, TNYA, CMPX, BHVN, FNA, EMBC, and ADUS
Should you be buying DICE Therapeutics stock or one of its competitors? The main competitors of DICE Therapeutics include Nuvalent (NUVL), Janux Therapeutics (JANX), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Tenaya Therapeutics (TNYA), Compass Therapeutics (CMPX), Biohaven (BHVN), Paragon 28 (FNA), Embecta (EMBC), and Addus HomeCare (ADUS). These companies are all part of the "medical" sector.
DICE Therapeutics vs.
Nuvalent (NASDAQ:NUVL) and DICE Therapeutics (NASDAQ:DICE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.
91.5% of DICE Therapeutics shares are owned by institutional investors. 14.8% of Nuvalent shares are owned by insiders. Comparatively, 4.9% of DICE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Nuvalent currently has a consensus target price of $44.50, suggesting a potential upside of 4.73%. DICE Therapeutics has a consensus target price of $62.60, suggesting a potential upside of 92.14%. Given DICE Therapeutics' higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than Nuvalent.
Nuvalent has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, DICE Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.
In the previous week, Nuvalent had 3 more articles in the media than DICE Therapeutics. MarketBeat recorded 9 mentions for Nuvalent and 6 mentions for DICE Therapeutics. DICE Therapeutics' average media sentiment score of 0.82 beat Nuvalent's score of 0.12 indicating that DICE Therapeutics is being referred to more favorably in the news media.
DICE Therapeutics received 10 more outperform votes than Nuvalent when rated by MarketBeat users. However, 55.56% of users gave Nuvalent an outperform vote while only 48.39% of users gave DICE Therapeutics an outperform vote.
Nuvalent has higher earnings, but lower revenue than DICE Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than DICE Therapeutics, indicating that it is currently the more affordable of the two stocks.
DICE Therapeutics' return on equity of -22.01% beat Nuvalent's return on equity.
Summary
DICE Therapeutics beats Nuvalent on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DICE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
DICE Therapeutics Competitors List
Related Companies and Tools